Island Pharmaceuticals : Updated Investor Presentation & Webinar Invitation

For personal use only

10 February 2022

ASX Announcement

Updated investor presentation and

webinar invitation

MELBOURNE Australia, 10 February 2022: Australian mid-clinical stage antiviral drug

development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to release a copy of an investor presentation that will be delivered to investors over the coming weeks.

In addition, Island announces its participation in the ShareCafe Small Cap "Hidden Gems" webinar, to be held tomorrow, Friday 11 February 2022 from 12:30pm AEDT / 9:30am AWST. Through the webinar, Chief Executive Officer Dr. David Foster will provide an update on Island's progress in moving lead drug candidate, ISLA-101 through to the clinic for dengue fever.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies. To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/5416151767246/WN_rJUuE_AySLqmpK1pJMzpXg

A recorded copy of the webinar will be made available following the event.

Approved for release to the ASX by:

Dr Paul MacLeman

Executive Chairman

Island

Pharmaceuticals Ltd

[e-mail]

Investors and media, for further information, please contact:

Jane Lowe

IR Department Mobile: [phone]

[e-mail]

About Island Pharmaceuticals

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviraltherapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia

For personal use only

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visitwww.islandpharmaceuticals.comfor more on Island.

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia

only SOLVING URGENT

useVIRAL DISEASE THREATS

ersonal(ASX: ILA)

Investor update - February 2022

DISCLAIMER

This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Island Pharmaceuticals).

Not an offer or financial product advice

onlyThe Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, r be relied on in connection with or act as any inducement or

rec mmendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the usepurposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the

law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any

views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

	person to engage in, or refrain from engaging in, any transaction.	Forward-looking statements, including projections, guidance on future
	Nothing in this presentation constitutes legal, financial, tax or other	operations, earnings and estimates (if any), are provided as a general
ersonal	guide only and should not be relied upon as an indication or guarantee
	advice. Recipients of the presentation should conduct their own
	investigation, evaluation and analysis of the business and other data and	of future performance. No representation is given that the assumptions
	information set out in the presentation.	upon which forward looking statements may be based are reasonable.
		This presentation contains statements that are subject to risk factors
	Fi ancial data All dollar values are in Australian dollars ($ or A$) unless	associated with the Group's industry. These forward-looking statements
	otherwise stated. Any financial data in this presentation is unaudited.	may be affected by a range of variables which could cause actual results
	Past performance The operating and historical financial information	or trends to differ materially, including but not limited to earnings,
	given in this presentation is given for illustrative purposes only and	capital expenditure, cash flow and capital structure risks and general
	sh uld not be relied upon as (and is not) an indication of the Company's	business risks.
ISLAND PHARMACEUTICALS LIMITED	2	INVESTOR PRESENTATION - FEBRUARY 2022

ISLAND AT A GLANCE

only	Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug
repurposing company, focused on the rapid development of
			antiviral therapeutics for infectious diseases
use	Island	Island's drug	Initial focus is
repurposing
Pharmaceuticals	on mosquito
strategy enables
lists on the ASX	borne diseases
rapid and
following	with a Phase II
efficient
ersonal	oversubscribed	development of	lead program
A$7.5m IPO in	in Dengue
antiviral
April 2021	fever
		therapies
ISLAND PHARMACEUTICALS LIMITED	3	INVESTOR PRESENTATION - FEBRUARY 2022